305 related articles for article (PubMed ID: 33496195)
1. Biomarkers of chronic spontaneous urticaria and their clinical implications.
Asero R; Cugno M
Expert Rev Clin Immunol; 2021 Mar; 17(3):247-254. PubMed ID: 33496195
[No Abstract] [Full Text] [Related]
2. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
3. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
4. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of Autoimmune Chronic Spontaneous Urticaria.
Larenas-Linnemann D
Curr Allergy Asthma Rep; 2023 Dec; 23(12):655-664. PubMed ID: 38064133
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune chronic spontaneous urticaria.
Kolkhir P; Muñoz M; Asero R; Ferrer M; Kocatürk E; Metz M; Xiang YK; Maurer M
J Allergy Clin Immunol; 2022 Jun; 149(6):1819-1831. PubMed ID: 35667749
[TBL] [Abstract][Full Text] [Related]
7. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria.
de Montjoye L; Darrigade AS; Giménez-Arnau A; Herman A; Dumoutier L; Baeck M
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):55-66. PubMed ID: 31965967
[No Abstract] [Full Text] [Related]
8. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
9. Chronic Spontaneous Urticaria: An Update on the Evaluation and Management.
Joshi SR; Anstey KM; Khan DA
Immunol Allergy Clin North Am; 2024 Aug; 44(3):503-515. PubMed ID: 38937012
[TBL] [Abstract][Full Text] [Related]
10. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.
Kolkhir P; Church MK; Altrichter S; Skov PS; Hawro T; Frischbutter S; Metz M; Maurer M
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):318-325.e5. PubMed ID: 31472293
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
12. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2022 Jan; 54(1):30-33. PubMed ID: 33555151
[No Abstract] [Full Text] [Related]
13. Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
Asero R; Ferrucci SM; Calzari P; Consonni D; Cugno M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108654
[TBL] [Abstract][Full Text] [Related]
14. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
[TBL] [Abstract][Full Text] [Related]
15. Biologics for chronic spontaneous urticaria: toward a personalized treatment.
Asero R; Ferrucci S; Tedeschi A; Cugno M
Expert Rev Clin Immunol; 2022 Dec; 18(12):1297-1305. PubMed ID: 36264653
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab in severe chronic urticaria: are slow and non-responders different?
Asero R
Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943
[No Abstract] [Full Text] [Related]
17. Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?
Asero R
Eur Ann Allergy Clin Immunol; 2020 Nov; 52(6):268-270. PubMed ID: 32191021
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study.
Schoepke N; Asero R; Ellrich A; Ferrer M; Gimenez-Arnau A; E H Grattan C; Jakob T; Konstantinou GN; Raap U; Skov PS; Staubach P; Kromminga A; Zhang K; Bindslev-Jensen C; Daschner A; Kinaciyan T; Knol EF; Makris M; Marrouche N; Schmid-Grendelmeier P; Sussman G; Toubi E; Church MK; Maurer M
Allergy; 2019 Dec; 74(12):2427-2436. PubMed ID: 31228881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
